Telemus Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Telemus Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-88	Closed	-$8K	–	492
2017 Q4	$8K	Buy	+88	New	+$7.63K	﹤0.01%	532

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Telemus Capital's LGND Position: Q1 2018 in Review

Telemus Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 88 shares — an estimated $8K sold.

Telemus Capital first reported a position in LGND in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

Telemus Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Telemus Capital sold 88 Ligand Pharmaceuticals shares in Q1 2018, an estimated $8K.
Telemus Capital first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Telemus Capital's Ligand Pharmaceuticals position peaked at $8K in Q4 2017.
326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on Telemus Capital's 13F filing for Q1 2018, filed 27 Apr 2018.